Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis

J Control Release. 2022 Mar:343:620-644. doi: 10.1016/j.jconrel.2022.02.009. Epub 2022 Feb 14.

Abstract

Multiple Sclerosis (MS) is an autoimmune disease with complicated immunopathology which necessitates considering multifactorial aspects for its management. Nano-sized pharmaceutical carriers named nanoparticles (NPs) can support impressive management of disease not only in early detection and prognosis level but also in a therapeutic manner. The most prominent initiator of MS is the domination of cellular immunity to humoral immunity and increment of inflammatory cytokines. The administration of several platforms of NPs for MS management holds great promise so far. The efforts for MS management through in vitro and in vivo (experimental animal models) evaluations, pave a new way to a highly efficient therapeutic means and aiding its translation to the clinic in the near future.

Keywords: Experimental autoimmune encephalomyelitis (EAE); Immune response; Multiple sclerosis (MS); Nanoparticles; Nanotechnology; Tolerance.

Publication types

  • Review

MeSH terms

  • Animals
  • Cytokines
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental* / drug therapy
  • Immunity, Cellular
  • Multiple Sclerosis* / drug therapy
  • Nanoparticles*

Substances

  • Cytokines